EcoSynthetix Inc.

Good morning, ladies and gentlemen. Thank you for standing by. Welcome to the EcoSynthetix 2026 Second Quarter Results Conference Call. At this time, all participants are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. Instructions will be provided for you at that time for questions. If anyone has any difficulty hearing the conference, please press Par 0 for operator assistance at any time. Listeners are reminded that portions of today's discussion may contain forward-looking statements that reflect current views with respect to future events. Any such statements are subject to risk and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. For more information on eco-synthetics, risks, and uncertainties related to these forward-looking statements, referred to the company's annual information form dated February 17, 2026, which is posted on CDAR. This morning's call is being recorded on Wednesday, July 29, 2026, at 8.30 a.m. Eastern Time. I would now like to turn the call over to Mr. Jeff McDonald, Chief Executive Officer of EcoSynthetix. Please go ahead, sir.

Thank you. Good morning, and thank you all for joining us. Yesterday afternoon, we reported our 2026 second quarter results. Sales were $4.5 million in the quarter, a decline of 9% compared to the same period last year. Adjusted EBITDA loss was $150,000, a decline of $390,000. As we mentioned in our last call, it is a continuation of the softness we saw in the first quarter with a couple of specific differences. Over the past few months, It's become clear that near-term uncertainty is affecting two strategic relationships, our key accounts in the pulp and wood composite end markets. That uncertainty has created the softness in our results. The technical performance and value proposition of our offering has been proven many times over with each of these customers and others. Our biopolymers continue to generate strong interest in our end markets, and our pipeline of prospects gives us confidence that as these market dynamics normalize, we are positioned with the right accounts to drive future growth. Let's break down what we're experiencing in each end market. In the pulp, tissue, and packaging end market, the major factor is the spread between the price of softwood pulp and hardwood pulp. That spread has narrowed to near zero in North America and Asia and is modestly positive in Europe. Independent reports show there is an oversupply of softwood being sold into the market to the point where it's been reported that 40% of the softwood merchant pulp capacity is being sold below cash costs. That's unsustainable in any industry. The long-term drivers for that spread to normalize remain intact, with additional hardwood capacity coming online and a net decrease in softwood capacity scheduled to close. You can see the spread on this chart. Historically, softwood trades between $200 and $300 more than hardwood. That spread is a healthy enough gap to support the value proposition of our offering to our strategic customer and of their enhanced pulp offering to their end customers. Our customer is a top 10 global pulp producer selling into a range of downstream applications. They're using our strength aids as an ingredient in a next generation hardwood pulp that offers comparable performance to the longer fiber softwood pulp. However, in today's environment, their customers can purchase softwood pulp at depressed prices, which reduces the incentive to switch. On the positive side, they have significantly increased their prospect pool with a reported 20% increase in their pipeline during 2026. They've also reported an extremely high technical success rate in their trial programs. Their customers are willing to do this technical work because they recognize the long-term trend. When that trend normalizes, they'll have the alternative of our customer's enhanced pulp. That's why our customer views the current softness as a slowdown until that spread reopens. On the development front, we continue to work with them to further optimize our strength aids for their pulp. They remain very engaged with our team at all levels, including purchasing, the commercial team, and R&D. In the tissue end market, we conducted an extended trial during the quarter with a top five global tissue producer, which has continued successfully into the third quarter. This first tissue line represents an approximate $200,000 annual opportunity, and based on the success so far, we've already begun work on two additional lines at this customer. We're excited about this opportunity as this account is one of the most progressive tissue manufacturers in the market with significant global expansion investments and a strong commitment to operational excellence. Today, this company has approximately 20 manufacturing facilities with over 30 tissue lines. This latest trial would represent a flagship account that others in the industry would take note of. During the quarter, despite the depressed softwood prices, we also expanded our pipeline and made progress with the North American-based tissue producers. To date, we have made most of our traction in the tissue end market with European-based producers. Expanding the opportunity set in North America is an important development. We recognize that you want us to move faster. We're aligned on that and are doing everything we can to expand and accelerate our opportunity set. The momentum we've built in the tissue market over the past two years is significant in the pulp and paper market, which has dealt with its own macro headwinds. We are encouraged by the accounts where we have gained traction and expanded share, and by the broader market reach we're building with our distribution partners. These partners are investing alongside us, and their progress in a challenging environment speaks to how well our product is performing in trials and commercial runs. In the wood composites and market, the macro drivers are different. Our key strategic account, which is an international retailer that's backward integrated into wood panel production, has reprioritized their business in the near term with a focus on low-cost products for everyone, given the global crisis of affordability. Their view is that simplification is key to addressing the complexity in their business to drive costs out. At this account, they run two glue systems, a conventional petroleum-based formaldehyde glue and our biopolymers. There is a cost to running two systems, and they ascribe that cost of complexity to our alternative. As a result, they've reduced the volume of our biopolymer they use. At the same time, they've told us they remain committed to their sustainability goals. It's a case of reprioritization and timing, not one of competitiveness or importance to their long-term future. Our solution is as technically viable and commercially competitive as ever. As a thought leader in the wood panel industry, the conviction this strategic account has for eliminating petroleum-based glues from its supply chain will set the standard for the market, but it is taking longer than we anticipated. In that vein, we continue to work on development projects with them that would create an even stronger and more permanent economic advantage over conventional glues. If we can reach the point where the economics are compelling under any commodity conditions, our biopolymer becomes the mainstream solution. As long as we continue to earn a return on their current business and they remain engaged in continuing to drive the program forward, we're committed to keep working with them. In the personal care end market, Dow started the year more slowly, which we believe was due to inventory stocking at the end of 2025. They picked back up to normalized levels in the second quarter. They remain bullish that 2026 will be another growth year following what was already a nice growth year in 2025. While volumes are modest on a relative basis compared to our other end markets, personal care remains a higher margin opportunity that supported the resilience of our bottom line in the quarter. We remain confident in the long-term opportunity ahead of us. We're driving ahead in our key end markets, and our strategy is the right one. There are no bio-based alternatives in the applications we target with as strong a commercial offering as ours. We've attracted Blue Chip customers and continue to add more. They're investing alongside us in development programs, trials, and new product offerings. We're in a bumpy period. There's no doubt about that. But we have the team, the capital, and the strategy to manage through and position the business for the other side. And with that, I'll turn it over to Rob to review the financials.

Rob? Thanks, Jeff, and good morning. Net sales for $4.5 million in Q2 2026 down 9% or $460,000 compared to the same period in 2025. The change was primarily due to lower sales volumes. As Jeff mentioned, lower sales volumes in key end markets reflect temporary market conditions. In wood composites, our key strategic account had a mill maintenance shutdown during the quarter and is now prioritizing manufacturing efficiency during a period of softer end market demand, resulting in lower durabine demand. In pulp, the unusually narrow price spread between hardwood and softwood pulp has reduced the economic incentive for premium products despite high trial success rates. Net of manufacturing depreciation, gross profit as a percentage of sales was 34% in the quarter, compared to 33% for the same period in 2025. The improvement was primarily due to lower manufacturing costs. SG&A expenses were $1.7 million in the quarter, compared to $1.2 million in the same period last year. The $420,000 change was primarily due to a change in foreign exchange gains and losses of $200,000, higher salaries and benefits of $100,000, and increased repairs and maintenance of $100,000. R&D expenses were $340,000 in the quarter, compared with $430,000 in the same period last year. The change primarily relates to refundable SR&ED taxes credits recognized in the current period. R&D expense as a percentage of sales was 7% for Q2 2026. Our R&D efforts continue to focus on further enhancing the value of our existing products and expanding our addressable opportunities. Adjusted EBITDA loss was $150,000 in the quarter compared to a positive adjusted EBITDA of $240,000 in the same period last year. The $390,000 decline in the quarter was primarily due to lower gross profit and higher operating costs adjusted for non-cash items. As of June 30th, we had $29.1 million of cash in term deposits compared to $29.6 million as of December 31, 2025. During Q2, we invested $150,000 in NCIB to purchase and retire 61,500 shares. Year to date, we've invested $730,000 to purchase and retire 307,000 shares. We have demonstrated our ability to responsibly manage your cash reserves through multiple cycles while continuing to invest in our long-term growth strategy. With that, I'll turn it back to Jeff for closing comments. Thanks, Rob.